NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers
NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers
NovaBay Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.
NovaBay Pharmaceuticals公司（纽交所股票代码：NBY），一家开发和推广高质量眼护产品的公司，与Eyenovia公司（纳斯达克股票代码：EYEN）合作推广协议正式启动。Eyenovia公司是一家商业阶段眼科公司，拥有两种FDA批准产品以及在儿童眼科前进性近视方面的后期资产。
Under the agreement, Eyenovia is leveraging its ten-person field salesforce to promote NovaBay's Avenova Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia's other FDA-approved products, MydCombi for mydriasis. In parallel, NovaBay has initiated reconnaissance and market preparation activities ahead of Eyenovia's launch of Clobetasol Propionate Ophthalmic Suspension, 0.05%, an innovative, rapid, sustained and more convenient solution for the treatment of postoperative inflammation and pain. Clobetasol is expected to be commercially available in August 2024. NovaBay will conduct outreach through its telephone-based physician dispensed channel to supplement geographic areas not covered by Eyenovia.
根据协议，Eyenovia公司利用其10人现场销售团队向一些大型眼科手术中心以及Eyenovia的其他FDA批准产品MydCombi进行推广，同时推广NovaBay的Avenova抗菌眼帘护理溶液。与此同时，NovaBay公司正在进行侦察和市场准备活动，为Eyenovia公司即将推出的Clobetasol Propionate Ophthalmic Suspension 0.05%做准备，这是一种更为便捷的治疗术后炎症和疼痛的创新、快速、持久的解决方案。预计Clobetasol将于2024年8月上市，NovaBay公司将通过其电话医师分发渠道开展推广，以补充Eyenovia公司未覆盖地区。